Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Noninferiority trialsSteven M SnapinnJournal of Biopharmaceutical Statistics|June 23, 2004
Alternatives for discounting in the analysis of noninferiority trialsSteven M SnapinnPharmacology|January 14, 2011
Statins for secondary prevention of cardiovascular disease: the right doseReynold Spector, Steven M SnapinnJournal of Biopharmaceutical Statistics|June 23, 2004
Separate modeling approaches for survival analysis with inaccurate covariate measurementsCong Chen, Steven M SnapinnTrials|October 27, 2007
Responder analyses and the assessment of a clinically relevant treatment effectSteven M Snapinn, Qi JiangStatistics in Medicine|November 6, 2003
Proportion of treatment effect (PTE) explained by a surrogate markerCong Chen, Hongwei Wang, Steven M SnapinnCurrent Controlled Trials in Cardiovascular Medicine|July 6, 2004
Informative noncompliance in endpoint trialsSteven M Snapinn, Qi Jiang, Boris IglewiczClinical Trials (London, England)|August 11, 2012
The issue of multiplicity in noninferiority studiesChunlei Ke, Beiying Ding, Qi Jiang, et al.European Heart Journal|August 3, 2006
Sex-based short- and long-term survival in patients following complicated myocardial infarctionVernon V S Bonarjee, Annika Rosengren, Steven M Snapinn, et al.Circulation|May 22, 2002
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJames L Januzzi, Steven M Snapinn, Peter M DiBattiste, et al.Pageof 3